Barar Jaleh, Javadzadeh Ali Reza, Omidi Yadollah
Cellular & Molecular Pharmaceutics, Tabriz University of Medical Sciences, Research Centre for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz, Iran.
Expert Opin Drug Deliv. 2008 May;5(5):567-81. doi: 10.1517/17425247.5.5.567.
Ocular drug delivery is an extremely challenging area due to its restrictive barrier functionalities.
Drug transport via corneal/non-corneal routes involves several intricate biological processes such as drug penetration across the ocular barriers and transfer to the anterior or posterior chambers, thus the influence of these processes on the pharmacotherapy of the eye should be fully addressed.
To pursue the impacts of such impediments in novel drug therapy, recent publications were reviewed regarding advanced strategies such as nanomedicines.
The ocular barriers are highly specialized and selectively control the inward/outward traverse of compounds, hence a better understanding of these biological obstacles would provide a platform to advance ophthalmic drug therapy towards specified delivery/targeting with minimal adverse consequences.
由于眼部具有限制性屏障功能,眼部药物递送是一个极具挑战性的领域。
药物通过角膜/非角膜途径的转运涉及多个复杂的生物学过程,如药物穿透眼部屏障并转移至前房或后房,因此应充分探讨这些过程对眼部药物治疗的影响。
为探究这些障碍在新型药物治疗中的影响,回顾了近期有关纳米药物等先进策略的出版物。
眼部屏障高度特殊,能选择性地控制化合物的向内/向外转运,因此更好地理解这些生物学障碍将为推进眼科药物治疗提供一个平台,以实现特定递送/靶向,同时将不良后果降至最低。